Sales and marketing expenses for the Q1 decreased approximately $5,700,000 or 48 percent to $6,200,000 compared to $11,900,000 for the same period in 2023, driven largely by strategic reductions in spending to reduce cash burn and improve operational flexibility. Research and development expenses decreased by $2,100,000 to $5,700,000 in the quarter, driven by reduced costs related to our FDA Audacity trial. General and administrative expenses of $6,400,000 increased by $1,100,000 dollars driven by $2,000,000 of costs related to being a public company and offset by $1,000,000 less bad debt expense in the period. Loss from operations for the Q1 was $11,400,000 a decrease of $2,500,000 compared to $13,900,000 in the same period in 2023. The decrease in loss from operations was driven by $6,800,000 in lower operating expenses, partially offset by the lower gross margin.